- Home
- INKT vs DYAI Comparison
INKT vs DYAI Comparison
Compare INKT & DYAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INKT
- DYAI
- Stock Information
- Founded
- INKT 2017
- DYAI 1979
- Country
- INKT United States
- DYAI United States
- Employees
- INKT N/A
- DYAI N/A
- Industry
- INKT Medicinal Chemicals and Botanical Products
- DYAI Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- INKT Health Care
- DYAI Health Care
- Exchange
- INKT Nasdaq
- DYAI Nasdaq
- Market Cap
- INKT 28.9M
- DYAI 29.6M
- IPO Year
- INKT 2021
- DYAI 2004
- Fundamental
- Price
- INKT $7.01
- DYAI $0.92
- Analyst Decision
- INKT Strong Buy
- DYAI Strong Buy
- Analyst Count
- INKT 2
- DYAI 1
- Target Price
- INKT $37.50
- DYAI $6.00
- AVG Volume (30 Days)
- INKT 14.7K
- DYAI 57.7K
- Earning Date
- INKT 08-12-2025
- DYAI 08-12-2025
- Dividend Yield
- INKT N/A
- DYAI N/A
- EPS Growth
- INKT N/A
- DYAI N/A
- EPS
- INKT N/A
- DYAI N/A
- Revenue
- INKT N/A
- DYAI $3,554,344.00
- Revenue This Year
- INKT N/A
- DYAI $22.56
- Revenue Next Year
- INKT N/A
- DYAI $30.95
- P/E Ratio
- INKT N/A
- DYAI N/A
- Revenue Growth
- INKT N/A
- DYAI 57.59
- 52 Week Low
- INKT $4.56
- DYAI $0.91
- 52 Week High
- INKT $13.79
- DYAI $2.20
- Technical
- Relative Strength Index (RSI)
- INKT 43.60
- DYAI 38.79
- Support Level
- INKT $6.80
- DYAI $0.95
- Resistance Level
- INKT $7.55
- DYAI $1.06
- Average True Range (ATR)
- INKT 0.34
- DYAI 0.06
- MACD
- INKT -0.03
- DYAI 0.00
- Stochastic Oscillator
- INKT 13.29
- DYAI 3.67
About INKT MiNK Therapeutics Inc.
MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. The company is advancing a pipeline of both native and next generation engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery.
About DYAI Dyadic International Inc.
Dyadic International Inc is a worldwide biotechnology platform company. It has developed a gene expression platform for producing commercial quantities of industrial enzymes and other proteins and has licensed this technology to third parties, such as Abengoa Bioenergy, BASF, Codexis and others, for use in industrial (non-pharmaceutical) applications. This technology is based on the Thermothelomyces heterothallica fungus, which the company named C1.